BioOrbit, a UK space-manufacturing startup, introduced BOX, a compact autonomous orbital manufacturing unit designed to crystallize protein-based drugs in microgravity, featuring a proprietary crystallization process for low-Earth orbit production. The company said BOX operates in orbit at roughly the size of a microwave and transforms biologic therapies into highly ordered crystalline forms to reduce viscosity.
BioOrbit stated that the process can enable the reformulation of intravenous antibody medicines into subcutaneous, self-injectable treatments while supporting scaled pharmaceutical production in orbit. The company also raised £9.8 million in seed funding to accelerate industrial deployment and contracted pharmaceutical programs, with investors including LocalGlobe and Breega.
For patients, orbital crystallization could shorten treatment times and expand at-home administration options, reflecting a broader trend of using space-based manufacturing environments to unlock new drug formulations and delivery models.
Microgravity Drug Manufacturing Systems
BioOrbit Launches Its BOX Orbital Manufacturing Unit
Trend Themes
-
Microgravity Crystallization — Enables formation of highly ordered protein crystals in low-Earth orbit that can alter drug solubility and stability compared with terrestrial processes.
-
Orbital Biomanufacturing — Could decentralize production of complex biologics by transferring critical formulation steps to compact autonomous units operating in space.
-
At-home Biologic Delivery — Shifts certain intravenous therapies toward subcutaneous, self-injectable formats through orbital-enabled reformulation, expanding possibilities for home administration.
Industry Implications
-
Pharmaceutical Manufacturing — Formation of superior crystalline biologics in microgravity has the potential to redefine upstream and downstream processing requirements for drug producers.
-
Space Logistics and Infrastructure — Demand for frequent, reliable transport and orbital-hosted modules may drive new supply chains and on-orbit service ecosystems tailored to pharmaceutical payloads.
-
Medical Devices and Delivery Systems — Novel low-viscosity crystalline biologics could prompt redesigns of injectors, pens, and cold-chain packaging to support at-home self-administration.